Literature DB >> 3660204

Immunohistochemical, electron microscopic, and morphometric studies of human prolactinomas after short-term bromocriptine treatment.

J Niwa1, T Minase, M Mori, K Hashi.   

Abstract

Two cases of human prolactinomas after short-term treatment with bromocriptine were studied by means of immunohistochemistry for prolactin, electron microscopy, and morphometry at the ultrastructural level. The results obtained showed an abundance of immunoreactive secretory granules in the tumor cells, a paucity in the electron microscopic images suggesting exocytosis of secretory granules, and no significant changes in the volume density of rough endoplasmic reticulum when compared with untreated (control) tumor cells. These findings strongly suggest that the effects of short-term bromocriptine treatment for lowering serum prolactin levels did not inhibit protein and secretory granule synthesis but rather caused a disturbance in the secretion of prolactin granules. The present morphometrical data suggest the possibility that a reduction in the number of cytoplasmic microtubules might be related to the disturbance of prolactin secretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3660204     DOI: 10.1016/0090-3019(87)90055-3

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  3 in total

Review 1.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

2.  Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.

Authors:  J J Orrego; W F Chandler; A L Barkan
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

3.  PET studies with L-[1-11C]tyrosine, L-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment.

Authors:  B J Daemen; R Zwertbroek; P H Elsinga; A M Paans; H Doorenbos; W Vaalburg
Journal:  Eur J Nucl Med       Date:  1991
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.